KENILWORTH, N.J.–(BUSINESS WIRE) October 15, 2020 — Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced
Continue reading »Home »
Results ‘encouraging’ from phase II trial for relapsed acute myeloid leukemia
There is a significant need for new treatments for patients with relapsed acute myeloid leukemia, a rare cancer of the
Continue reading »